Long Grove Pharmaceuticals offers generic methadone hydrochloride injection, USP, as part of its sterile injectable portfolio. Methadone hydrochloride injection, USP, is approved by the US FDA to treat moderate to severe pain that has not responded well to other forms of pain management and for detoxification and treatment of opioid use disorder. Methadone hydrochloride injection, USP, is available in a 200 mg/20 mL (10 mg/mL) vial and is manufactured in the United States. The product was approved by the FDA under an abbreviated new drug application (ANDA) and is bioequivalent to the same product manufactured by Mylan Pharmaceuticals. This product features clear, high-contrast labeling and integrated bar coding to support bedside scanning and help prevent medication errors. The product has a black box warning.